January 30th 2023
Results from the phase 1/2 CodeBreaK 100 trial indicate that sotorasib yields positive anticancer activity and safety in patients with pancreatic cancer harboring KRAS p.G12C mutations.
Phase 3 Study Explores Pamrevlumab for Unresectable LAPC
February 17th 2021The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.
Phase 3 TRYbeCA-1 Trial in Second-Line Pancreatic Cancer Will Continue to Final Analysis
February 9th 2021Per a planned interim superiority analysis conducted by an independent data monitoring committee, a trial of Eryaspace will continue without modification with final results anticipated later this year.
Improved Risk Models Identify People at Higher than Normal Risk of Pancreatic Cancer
May 2nd 2020Researchers demonstrated that risk models that include established clinical, genetic, and circulating factors are better able to identify people at significantly higher than normal risk of pancreatic cancer over those using clinical factors alone.
Stereotactic Body Radiation Therapy Improves OS for Locally Advanced Pancreatic Cancer
March 10th 2020An international systematic review and meta-analysis indicated that stereotactic body radiation therapy compared to conventionally fractioned radiation therapy with concurrent chemotherapy may offer a modest improvement in OS with a more favorable toxicity profile.
Eileen M. O’Reilly, MD, on the Challenges of Treating Patients with Pancreatic Cancer
January 27th 2020The medical oncologist from Memorial Sloan Kettering Cancer Center discussed challenges in treating patients with pancreatic center, and also the challenge of obtaining effective drugs in the clinical setting.
Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?
August 23rd 2019A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.